Men who received androgen deprivation therapy for prostate cancer were 54% more likely to be diagnosed with non-alcoholic fatty liver disease than those who did not, a study found.
The risk being lost to follow-up while on active surveillance for prostate cancer is higher among blacks than whites, according to a study.
LUTS treatment with the alpha-blocker prazosin was associated with significantly lower 2- and 5-year biochemical recurrence rates vs tamsulosin and non-use of alpha-blockers.
Novel imaging and tumor biomarker assays are likely to define non-metastatic castration-resistant prostate cancer more accurately, authors of new review state.
Low-dose-rate brachytherapy is associated with excellent long-term biochemical control and survival, new study finds.
Even low cumulative exposure to physical strain at work is associated with a decreased risk of prostate cancer, study finds.
In a study, men with low-risk prostate cancer were nearly 2-fold more likely to be managed with observation if they had a prostate MRI during the diagnostic work-up.
At a major tertiary referral center, the use of radical prostatectomy for insignificant prostate cancer decreased from 15% in 2009 to 3% in 2016, a study found.
A patient's risk of suicide is doubled within the first year following a prostate cancer diagnosis, according to a new meta-analysis.
Study of Korean radical prostatectomy patients showed that those who were obese had significant increased odds of biochemical recurrence and cancer-specific mortality
Cytoreductive radical prostatectomy (RP) for metastatic prostate cancer (PCa) is associated with higher complication rates and longer hospital stays than RP for non-metastatic PCa.
Identification of DNA repair defects within prostate cancer tissue may enable a precision oncologic approach to treatment.
From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.
Physicians increasingly are prescribing high dose and very high dose radiation therapy after radical prostatectomy despite an absence of randomized trials supporting the practice.
Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.
Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.
Radiation therapy dose escalation, pelvic lymph node irradiation, and hormone therapy duration are prescribed based on patient and tumor characteristics.
Men in the bottom 10th of free testosterone level vs those with higher levels were found to have a 23% decreased risk of prostate cancer.
Younger men with prostate cancer are less likely to experience Gleason score upgrading and pathologic progression on repeat biopsy.
According to researchers, 57.3% of men who underwent salvage robot-assisted radical prostatectomy were pad-free at 12 months.
New study shows no significant difference in overall survival between 18 and 36 months of androgen deprivation therapy used in combination with radiation therapy.
Regardless of treatment modality, men with Gleason 10 prostate cancer have high 5-year overall survival rates, new study finds.
Early study results are encouraging, but high-quality data that validate PET/CT against a reliable reference standard are lacking.
MRI with targeted prostate biopsy plus systematic biopsy fails to improve detection of upgrading in men on active surveillance for prostate cancer vs systematic biopsy alone.
This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
Pulmonary embolism is associated with GnRH agonist use and orchiectomy.
The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.
Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17% among those with mCRPC.
Failure-free survival was 88% at 5 years among patients with nonmetastatic prostate cancer who underwent focal therapy with high-intensity focused ultrasound.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)